Printer Friendly

Empi Inc. to Launch New Electrotherapy Device Incorporating Outcomes Measurement and Documentation Capability.

ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 17, 1997--Empi Inc., a medical device manufacturer, today announced that the Food and Drug Administration has granted it clearance to market the Epix(R) VT, a new transcutaneous electrical nerve stimulation (TENS) device with outcomes measurement and documentation capability.

Epix(R) VT is currently in limited release and is being introduced this week at the American Academy of Pain Management in New Orleans. It will be available for national distribution in January. The product has been developed to meet the needs of physicians and payors who desire objective outcome information to validate the effectiveness of TENS for any given patient.

"The Epix(R) VT TENS device reaffirms Empi's traditional leadership position in electrotherapeutic pain management systems design and development," said Joseph E. Laptewicz, Empi's president and chief executive officer. "The product incorporates a validated pain scale, as well as other treatment measurements, which enable clinicians to objectively assess the device's usefulness for specific patients on an individual basis. The technology also allows the clinician to tailor treatment regimens and intensity levels to specific patient needs using objective outcomes measurements built into the system's capabilities. These design features and benefits have been developed and made available in Epix(R) VT to further strengthen the argument that high intensity TENS is a most cost effective treatment alternative for pain management and help solidify reimbursement levels worldwide."

Laptewicz concluded, "Empi is very pleased to be able to offer the new technology available in the Epix(R) VT to our patients, providers, and payors who have requested real-time outcomes measurement capability. Empi remains committed to the development, licensing, and acquisition of new technology in the iontophoretic drug delivery, orthotics, and incontinence therapeutic markets as part of our continuing diversification strategy to reinforce our leadership position in the treatment of patients with functional disabilities."

Certain statements made in this press release relating to the availability of the Epix(R) VT device in January and its ability to meet certain needs of physicians and payors are forward-looking statements and are subject to risks and uncertainties which could cause actual results to differ materially from those projected.

Empi Inc. develops, manufactures, and markets non-invasive biomedical devices and accessories for use in the physical therapy, sports medicine, and incontinence treatment markets. The company's shares are traded on the Nasdaq Stock Market's National Market under the symbol EMPI.

CONTACT: Empi Inc., St. Paul

Patrick Spangler, 612/415-7404
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 17, 1997
Previous Article:Fed One Bancorp Increases Dividend.
Next Article:Wilson McHenry Company Hires Specialists in Consumer Product Marketing; Leeann Lavin and Marcy Dockery Bring Extensive Experience in High-Tech Media...

Related Articles
Cranial electrotherapy stimulation: a safe neuromedical treatment for anxiety, depression, or insomnia.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters